Valve-in-valve TAVR may replace surgical re-replacement in aortic bioprosthesis failure
Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) leads to better short-term outcomes than redo surgical aortic valve replacement (SAVR) in patients treated for aortic bioprosthesis failure, a recent study has shown. During long-term follow-up, no difference is seen in major cardiovascular outcomes between the two treatment arms.